Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

ClinicalTrials.gov ID: NCT01890265

Public ClinicalTrials.gov record NCT01890265. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis

Study identification

NCT ID
NCT01890265
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Kyntra Bio
Industry
Enrollment
160 participants

Conditions and interventions

Interventions

  • Pamrevlumab Drug
  • Placebo Drug
  • Sub-Study: Pirfenidone Drug
  • Sub-Study: Nintedanib Drug

Drug

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 29, 2013
Primary completion
Nov 15, 2017
Completion
Nov 15, 2017
Last update posted
Sep 3, 2020

2013 – 2017

United States locations

U.S. sites
26
U.S. states
22
U.S. cities
26
Facility City State ZIP Site status
The Kirklin Clinic Birmingham Alabama 35294
David Geffen School of Medicine at UCLA Los Angeles California 90024
UC Davis Medical Center Sacramento California 95817
National Jewish Health Denver Colorado 80206
Yale University New Haven Connecticut 06520
Pulmonary Disease Specialist, PA Kissimmee Florida 34741
Pensacola Research Consultants, Inc., d.b.a. Avanza Medical Research Center Pensacola Florida 32504
Emory University Atlanta Georgia 30322
Northwestern University Chicago Illinois 60611
University of Kansas Medical Center Kansas City Kansas 66160
Via Christi Clinic, P.A. Wichita Kansas 67208
University of Louisville Louisville Kentucky 40202
University of Maryland Baltimore Maryland 21201
Steward St. Elizabeth's Medical Center Boston Massachusetts 02135
Henry Ford Medical Center Detroit Michigan 48202
St. Luke's Hospital Chesterfield Missouri 63017
Columbia University Medical Center New York New York 10032
PulmonIx LLC Greensboro North Carolina 27403
University of Cinncinati Cincinnati Ohio 45267
Dartmouth-Hitchcock Medical Center Lebanon Ohio 03756
Legacy Research Institute Portland Oregon 97210
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213
Vanderbilt University Nashville Tennessee 37232-5735
University of Texas Southwestern Medical Center Dallas Texas 75390
University of Utah - Lung Health Research Salt Lake City Utah 84108
Vermont Lung Center Colchester Vermont 05446

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01890265, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 3, 2020 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01890265 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →